You are here: Industry Insights > VLA2001

News List

Valneva to Host Symposium on COVID-19 and Chikungunya Vaccine Candidates at 31st European Congress of Clinical Microbiology & Infectious Diseases firstwordpharma
July 06, 2021
ValnevaSE announced today it will host a virtual symposium titled, "Developing new vaccines to protect against infectious diseases at home and abroad" on July 9, at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID）
Valneva completes Phase 3 trial recruitment for its inactivated COVID-19 vaccine candidate worldpharmanews
June 10, 2021
Valneva SE announced that it has completed recruitment for the pivotal Phase 3 trial of its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.
Pharm-Olam is now enrolling UK volunteers into a pivotal Phase III COVID-19 vaccine study prnewswire
May 21, 2021
Pharm-Olam, a global, midsized CRO offering full-service clinical development solutions for infectious diseases, vaccines, rare diseases, and oncology, is now enrolling UK volunteers into a pivotal Phase III COVID-19 vaccine study.
Inactivated COVID-19 vaccine candidate enters comparative immunogenicity trial europeanpharmaceuticalreview
April 26, 2021
The Phase III trial aims to demonstrate that Valneva’s VLA2001 is more immunogenic than AstraZeneca’s conditionally approved COVID-19 vaccine, Vaxzevria.
Valneva’s Inactivated, Adjuvanted COVID-19 Vax Achieves Positive Data contractpharma
April 23, 2021
VLA2001 was highly immunogenic with more than 90% of study participants developing significant levels of antibodies to SARS-CoV-2 virus spike protein.
Valneva Focuses on Bilateral Discussions to Supply COVID-19 Vax contractpharma
April 23, 2021
Valneva SE is now focusing on discussions, on a country by country basis, to supply its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001, and is consequently deprioritizing the ongoing centralized discussions with the European Commission (EC).
Valneva Switches Focus to Bilateral Discussions to Supply its Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001 americanpharmaceuticalreview
April 22, 2021
Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, announced it is now focusing on bilateral discussions ...
Scottish COVID-19 vaccine shows ‘strong immune response’ in early UK trials expresspharma
April 08, 2021
The vaccine, called VLA2001, also induced T-cell responses, which help the body fend off a virus and determine long-lasting immunity.
Valneva reports positive Phase 1/2 data for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001 worldpharmanews
April 07, 2021
Valneva SE announced positive data for Part A of the Phase 1/2 clinical trial of its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.
Valneva Begins Manufacturing of Inactivated, Adjuvanted COVID-19 Vaccine, Completes Study Recruitment americanpharmaceuticalreview
February 05, 2021
Valneva has commenced production of its inactivated, adjuvanted COVID-19 vaccine candidate in parallel to the ongoing clinical studies, in order to optimize the timeline for potential deliveries of the vaccine.

Previous page 1 2 3 Next page